Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov Sells 16,667 Shares

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov sold 16,667 shares of the company’s stock in a transaction on Friday, May 16th. The stock was sold at an average price of C$9.49, for a total transaction of C$158,203.16.

Rostislav Christov Raykov also recently made the following trade(s):

• On Friday, April 4th, Rostislav Christov Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$7.46, for a total transaction of C$74,550.00.
• On Wednesday, March 5th, Rostislav Christov Raykov sold 7,569 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$9.71, for a total transaction of C$73,503.54.

Fennec Pharmaceuticals Price Performance

FRX traded up C$0.84 during midday trading on Monday, hitting C$9.50. The company had a trading volume of 300 shares, compared to its average volume of 1,234. The company has a debt-to-equity ratio of -620.83, a quick ratio of 10.17 and a current ratio of 7.80. The company has a market capitalization of C$183.20 million, a PE ratio of -160.93 and a beta of 0.25. Fennec Pharmaceuticals Inc. has a twelve month low of C$5.65 and a twelve month high of C$10.14. The firm’s 50-day simple moving average is C$8.25 and its 200-day simple moving average is C$8.41.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.